Skip to main content
Malin Corporation Plc logo

Malin Corporation Plc — Investor Relations & Filings

Ticker · MLC ISIN · IE00BVGC3741 LEI · 635400JG4YSDU5U1YU17 IR Financial and insurance activities
Open in API
Filings indexed 180 across all filing types
Latest filing 2022-05-04 Remuneration Information
Country IE Ireland
Listing IR MLC

About Malin Corporation Plc

http://malinplc.com/

Malin Corporation Plc is an investment company that provides long-term capital and operational expertise to highly innovative life sciences companies. The company focuses on private businesses operating in the therapeutics, medical devices, and diagnostics sectors. Its investment strategy is concentrated on specific therapeutic areas, primarily oncology, immunology, and genetic diseases. Malin supports its portfolio companies across various stages of development, from initial science and discovery through to clinical and commercial phases, with the objective of fostering the development of transformative technologies and outcomes for patients.

Recent filings

Filing Released Lang Actions
Block listing Interim Review
Remuneration Information Classification · 99% confidence The document is identified by the header 'RNS Number : 0847K' and contains a 'Schedule 6 - BLOCK LISTING SIX MONTHLY RETURN'. This schedule details the balance of unallotted securities under an incentive plan over a specific period (Nov 2021 to May 2022) and the total number of securities issued. This type of filing, which reports on the status of securities related to employee/incentive plans, is a specific regulatory disclosure. While it relates to capital structure, it is not a general financing announcement (CAP) or a share repurchase (POS). Since it is a formal, structured regulatory return provided via RNS, and it doesn't fit perfectly into the other specific categories like 10-K, ER, or DIV, it falls best under the general 'Regulatory Filings' category (RNS) as a specific type of disclosure required by the exchange, or potentially a specialized filing not explicitly listed. Given the options, RNS is the most appropriate catch-all for structured regulatory updates that aren't standard financial reports or corporate actions like dividends/M&A. However, looking closely at the definitions, this is a formal return detailing security movements, which is a type of regulatory disclosure. Since 'RNS' is defined as 'General regulatory announcements and fallback category for miscellaneous filings that do not neatly fit into other specific categories,' and this is a highly specific, non-standard report format, RNS is the best fit.
2022-05-04 English
Mycovia announces FDA approval of VIVJOA
Regulatory Filings Classification · 100% confidence The document is identified by the 'RNS Number' header and contains boilerplate language typical of regulatory news service announcements, specifically mentioning 'RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.' The content announces a significant event (FDA approval for an investee company's drug) and provides a link to the full press release PDF. Given the short length (4142 chars) and the nature of announcing external news/filings rather than being the comprehensive report itself, this fits the definition of a general regulatory announcement or news service filing. Since it doesn't fit specific categories like Director's Dealing (DIRS), Earnings Release (ER), or Capital Change (CAP), the most appropriate fallback is Regulatory Filings (RNS).
2022-04-28 English
Notice of 2022 AGM & Directorate Change
Board/Management Information Classification · 99% confidence The document is an RNS announcement (indicated by 'RNS Number' and the footer mentioning RNS/London Stock Exchange) dated April 26, 2022. The primary content announces two key items: 1) The issuance of the 'Letter from the Chair, Notice of Annual General Meeting ("AGM") and Form of Proxy' and provides the date/location for the 2022 AGM. 2) An announcement of a Directorate Change (appointment and resignation). Since the document primarily serves as a notice about the upcoming AGM materials and simultaneously reports a management change, it strongly relates to AGM information and management changes. However, the core purpose of the announcement is to notify shareholders about the AGM logistics and related documents. The most specific category covering the AGM notice is 'AGM-R' (AGM Information). While it contains management change information (MANG), the context is tied directly to the AGM notice being issued. Given the explicit mention of 'Notice of Annual General Meeting ("AGM")' and the document being a short regulatory news service release, AGM-R is the best fit, although RPA or MANG are secondary considerations. I will prioritize AGM-R as the AGM notice is the headline event being communicated.
2022-04-26 English
Malin Announces 2021 Full Year Results
Earnings Release Classification · 95% confidence The document is an RNS (Regulatory News Service) announcement from Malin Corporation plc titled '2021 Full Year Results'. It provides a summary of financial highlights, operational milestones, and divestments for the fiscal year 2021. Crucially, it explicitly states that the company 'today publishes its full year results and annual report' and directs readers to the company website to view the full report. Because this document is a summary announcement of the annual report rather than the full annual report itself, and it follows the standard RNS format for such announcements, it is classified as an Earnings Release (ER) as it serves as the initial announcement of financial results. FY 2021
2022-03-15 English
Notice of Results
Report Publication Announcement Classification · 99% confidence The document is very short (3365 characters) and its primary purpose is to announce *when* and *how* the company's 'Full Year 2021 Results' and '2021 Annual Report' will be published (March 15, 2022). It explicitly states the results press release and presentation will be available on that date and provides conference call details. According to Rule #2 (The 'MENU VS MEAL' Rule), a short announcement stating that a report will be published or is attached classifies as a Report Publication Announcement (RPA). It is not the full 10-K or ER itself, but the notice about their release.
2022-03-08 English
Immunocore announces FDA approval of KIMMTRAK®
Regulatory Filings Classification · 100% confidence The document starts with 'RNS Number : 7727Z' and is dated January 27, 2022. It is a brief announcement from Malin Corporation plc regarding an FDA approval received by one of its investee companies (Immunocore). The text explicitly mentions that a copy of the full press release is available via a link ('A copy of Immunocore's press release is available to view below:'). The document length is short (4653 chars), and it functions as a notification of an event/publication rather than the full report itself. This structure strongly indicates a Regulatory Filing (RNS) or a Report Publication Announcement (RPA). Since it is a general regulatory news service announcement (RNS is mentioned multiple times, including the footer), RNS is the most appropriate general category for this type of market-sensitive news release that doesn't fit a more specific financial report type.
2022-01-27 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.